According to Zhitong Finance App, Jincheng Pharmaceutical (300233.SZ) announced that Shanghai Jincheng Suzhi Pharmaceutical Co., Ltd. (hereinafter referred to as “Jincheng Suzhi”), a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for bisoprolol fumarate tablets issued by the State Drug Administration. Bisoprolol fumarate tablets are a highly selective beta1-adrenal receptor blocker (cardioselective) used for hypertension, coronary heart disease (angina), and chronic stable heart failure with decreased left ventricular contractility (ejection fraction ≤ 35%).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.